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Background: Individuals with the CDKL5 disorder have been described as having severely impaired development.
A few individuals have been reported having attained more milestones including walking and running. Our aim
was to investigate variation in attainment of developmental milestones and associations with underlying genotype.
Methods: Data was sourced from the International CDKL5 Disorder Database, and individuals were included if they
had a pathogenic or probably pathogenic CDKL5 mutation and information on early development. Kaplan-Meier
time-to-event analyses investigated the occurrence of developmental milestones. Mutations were grouped by their
structural/functional consequence, and Cox regression was used to investigate the relationship between genotype
and milestone attainment.
Results: The study included 109 females and 18 males. By 5 years of age, only 75% of the females had attained
independent sitting and 25% independent walking whilst a quarter of the males could sit independently by 1 year
3 months. Only one boy could walk independently. No clear relationship between mutation group and milestone
attainment was present, although females with a late truncating mutation attained the most milestones.
Conclusion: Attainment of developmental milestones is severely impaired in the CDKL5 disorder, with the majority
who did attain skills attaining them at a late age. It appears as though males are more severely impaired than the
females. Larger studies are needed to further investigate the role of genotype on clinical variability.
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encephalopathyBackground
The majority of research on individuals with mutations
in the cyclin-dependent kinase-like 5 (CDKL5) gene has
been limited to case studies and small case series (n = 20)
[1-3]. These studies have predominantly focused on
individuals with the early-onset seizure variant of Rett
syndrome (RTT). However, using information collected
through the International Rett Syndrome Phenotype
Database (InterRett) [4], we found that only a small pro-
portion of individuals with a CDKL5 mutation met the
clinical criteria for the early-onset seizure variant of RTT,
which specifically requires a period of developmental* Correspondence: Jenny.Downs@telethonkids.org.au
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unless otherwise stated.regression [5]. We therefore suggested that the term
‘CDKL5 disorder’ was a more appropriate terminology
for individuals with a mutation in the CDKL5 gene.
The literature suggests that individuals with the CDKL5
disorder rarely experience normal development and that
the majority have refractory epilepsy with onset within the
first few months of life and severe global developmental
delay [6-8]. There has however been a small proportion
reported with the ability to walk and even to run [9-12],
suggesting that the clinical severity may be more variable
than originally thought. Variability in clinical presentation
is also seen in RTT, which is mostly associated with muta-
tions in the methyl-CpG binding domain-2 gene (MECP2)
[5]. This clinical variability has resulted in ‘variant’ types
being described and studies focusing on investigating
the relationship between clinical presentation and spe-
cific mutations [13-15]. For caregivers and clinicians, it isis is an Open Access article distributed under the terms of the Creative
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ther examined so that appropriate prognostic information
can be provided. Further investigation is needed to de-
velop a better clinical overview of the development and at-
tainment of milestones in this disorder. Our aim was to
describe the attainment of gross motor, hand function,
communication and other developmental milestones in
individuals with the CDKL5 disorder. We also investigated
the relationship between the timing of these events and
genotype.
Methods
Information on individuals with the CDKL5 disorder
was obtained from the newly developed International
CDKL5 Disorder Database, which was established in
September 2012. Data is collected from caregivers in the
form of online or paper-based questionnaires. Caregivers
were asked to refer to their child’s infant health record,
diaries or available medical records when completing the
questionnaire. Cases were included in this study if the indi-
viduals CDKL5 mutation was considered to be pathogenic
or probably pathogenic, and the caregiver had completed
the questionnaire section on early development. Due to
the heterogeneity of mutations within our sample, each in-
dividual’s mutation was grouped according to its predicted
structural/functional consequence [16]. These groups were
a) mutations causing no functional protein which included
mutations resulting in a loss of the functional components
in the catalytic domain (portion of protein responsible for
kinase activity) before amino acid (aa) 172 and all full gene
deletions, b) missense/in-frame mutations within the cata-
lytic domain which included any missense mutations
within the protein kinase active region or in-frame muta-
tions (such as a deletion resulting in loss of some of the
kinase region but subsequent protein is intact), c) truncat-
ing mutations located from aa 172 to aa 781 inclusive
which includes any mutations resulting in a truncationFigure 1 Schematic representation of the CDKL5 protein and our mu
and the C-terminal region in white. Modified from ‘What We Know and Woul
[17]. TEY motif Thr-Glu-Tyr motif, NLS1 and NLS2 nuclear localisation signals 1 ansuch as nonsense or frameshift mutations resulting in main-
taining kinase activity but loss of c-terminal region and
d) truncating mutations occurring after aa 781 and therefore
maintaining kinase activity and majority of the c-terminal
region (Figure 1).
To investigate early development, we included infor-
mation on the age of attainment of the following major
developmental milestones: sitting, standing and walking
independently; raking grasp and pincer grip; and babble
and use of single words. The timing of attainment of these
milestones was investigated using Kaplan-Meier time-to-
event analysis. This allows an appropriate estimate of the
proportion of individuals who will attain a skill by a par-
ticular age whilst taking into account those who are still
yet to attain the skill. To investigate the relationship be-
tween mutation type and the attainment of these particular
milestones, separate time-to-event analyses by mutation
group were undertaken and the median age and propor-
tion that attained each skill determined. Cox regression
was used to investigate the relationship between each skill
and mutation group.
Information on the attainment of additional milestones,
for which we did not collect an age of attainment, was also
included. For these skills, individuals were grouped accord-
ing to their current age at time questionnaire completion
(younger than 1.5 years; 1.5 to <7 years; 7 to <13 years; and
13 years and older) and we determined the proportion of
each age group who had attained the milestone of interest.
These age groups were chosen based on the expected de-
velopmental level of the children. All the milestones in-
cluded in our study (excluding the use of phrases) would
have been achieved by 1.5 years of age in a normally devel-
oping child. We therefore grouped those aged 1.5 years
and under as it was likely that these children were yet to
attain many of these skills. This allowed us to account for
young individuals who had not yet had the opportunity to
attain these skills.tational grouping. Legend: The catalytic region is shown in light grey
d Like to Know about CDKL5 and its Involvement in Epileptic Encephalopathy ’
d 2, NES nuclear export signal.
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Results
As of May 2014, there were 127 individuals for whom
information on early development had been provided.
Of these, 109 (86%) were female (median age 6.1 years,
range 3 months to 29 years) and 18 (14%) were male
(median age 4.6 years, range 10 months to 22.7 years).
The distribution of mutations within our sample is
shown in Table 1. We have also included information on
our determination of whether missense mutations were
likely pathogenic (Table 2).
Time-to-event analysis of attainment of developmental
milestones
Information on the age of attaining independent sitting
was available for all but four females, of whom 59 (56%)
had attained independent sitting. The median age at
attainment of independent sitting was 3 years (range
6 months to 5 years) with almost three quarters achieving
unaided sitting by 5 years of age (Figure 2). Independent
standing was attained by 26% of females (n = 27/105), and
a quarter was able to stand independently by 5 years
(range 10 months to 6 years 11 months). Independent
walking was attained by 22% of females (n = 24/109), and
time-to-event analysis showed that a quarter had attained
independent walking by 4 and a half years (range 1 year
6 months to 6 years 5 months). For the 18 boys in our
study, information on the age of attaining sitting was
known for all but one, of whom six could sit independ-
ently with a quarter attaining independent sitting by 1 year
3 months (range 8 months to 3 years) (Figure 2). Two boys
were able to stand independently by 1 year 10 months,
and one boy was able to walk independently at 1 year
11 months.
The age that a raking grasp was attained was known
for 92 females of whom 45 (49%) had attained a raking
grasp at a median age of 5 years (range 5 months to
12 years) (Figure 2). A pincer grasp was attained by 13%
of females (n = 14/106) of whom 10% had attained a pin-
cer grip by 3 years (range 1 to 12 years). For the males,
information was available for all but one on the age of
attaining a raking grasp. Ten percent of the males attained
a raking grasp by 1 year 10 months and one male attained
a pincer grasp at 2 years of age (Figure 2).
Information on the age that babbling was attained was
available for 97 females of whom 43 (44%) had attained
babble. A quarter of whom achieved babble by 1 year of age
(range 3 months to 6 years) and just under a half by 6 years
(Figure 2). Single words were attained by 16% (n = 17/105),
and 10% would attained single words by 1 year 6 months
and just under a quarter by 7 years of age (range 9 monthsto 7 years). Of the males in our study, information on age
of attaining babble was available for all but three (n = 15)
of whom five attained the ability to babble. A quarter
attained babble by 7 months of age (range 6 months to
1 year 8 months) (Figure 2). There was one boy who spoke
single words at 3 years of age.
The proportion of females and males who attained
other gross motor, fine motor and communication skills
not included in the time-to-event analysis is shown in
Table 3.
Relationship between genotype and attainment of
developmental milestones for females
A higher proportion of females with a truncating mutation
after aa 781 attained gross motor, hand function and com-
munication milestones than the other groups (Table 4). Al-
though there was a visible difference between the groups
shown in Figure 3, there were no clear relationships, al-
though females with a truncating mutation after aa 781
were more likely to have attained independent sitting than
the those with no functional protein (HR: 2.4, p value
0.026, 95% CI 1.11–5.36).
Discussion
The acquisition of developmental milestones was se-
verely impaired in our sample of individuals with the
CDKL5 disorder. This was especially true for males, with
nearly half not achieving any of the major gross motor,
communication or hand function milestones investi-
gated. There was variability, with a few girls eventually
attaining most if not all of the milestones we investi-
gated. If milestones were attained, they were significantly
delayed. Despite small numbers, it appears as though
mutation type may play some role in this variation, with
girls with a truncating mutation after aa 781 attaining
more milestones than those who had a mutation result-
ing in no functional CDKL5 protein.
Our study has shown that there is variability in the at-
tainment of developmental milestones within the CDKL5
disorder. The majority of females did achieve some mile-
stones, most frequently involving gross motor skills. For
most, these milestones were attained at an older age than
expected for the general population [30]. Using time-to-
event analysis, we found that 10% of females would attain
independent sitting by 10 months, by 1 year 2 months a
quarter attained independent sitting and by 5 years nearly
three quarters had attained independent sitting. In our
entire female population, only 22% attained independent
walking compared to 31% of our 7- to 13-year group. Time-
to-event analysis indicated that 25% of our group attained
this skill by 4 and a half years of age. This delay in attain-
ment of milestones occurred across developmental areas
and may explain why other studies have found females with
the CDKL5 disorder to attain less developmental milestones
Table 1 Distribution of CDKL5 mutations within our study group






No functional protein c.-253-?_-163 + ?del p.(0) 1 2 (F) Yes Yes [4]
No functional protein c.-253-?_-163 + ?del p.(0?) 1 1 (F) Yes Yes [4]
No functional protein c.-253-?_99 + ?del p.(0) 1–3 1 (F) Yes Yes [4]
No functional protein c.64 + 2 T > C p.(0) 2 1 (F) Yes No
No functional protein c.64 + 1G > A p.(0) 2 1 (F) Yes Yes [4]
No functional protein c.-162-?_99 + ?del p.(0) 2–3 1 (F) Yes Yes [4]
No functional protein c.-162-?_99 + ? p.(0) 2–3 1 (F) No No
No functional protein c.-253-?_*1085del p.(0) 1–21+ 1 (F) No No
No functional protein c.-253-?_*1085del p.(0) 1–21 3(F) No No
No functional protein c.-253-?_*1085del p.(0) 1–21+ 1 (F) No No
No functional protein c.-253-?_*1085del p.(0) 1–21+ 1 (F) Yes Yes [4]
No functional protein c.-253-?_*1085del p.(0) 1–21+ 1 (F) No No
No functional protein c.65-?_99 + ?del p.(Ala23Asnfs*3) 3 2 (F and M) Yes Yes [4]
No functional protein c.99 + 5G > A p.Ala23Asnfs*3 3 1 (F) Yes Yes [2,4]
No functional protein c.100-?_*1085del p.(?) 4–21+ 1 (F) No No
No functional protein c.146-1G > A p.(Asn50Tyrfs*15) 5 1 (M) No No
No functional protein c.146-6 T > G p.(Glu49Valfs*2) 5 1 (F) No No
No functional protein c.146-?_282 + ?del p.(Asn50Tyrfs*15) 5 1 (F) Yes Yes [4]
No functional protein c.163_166delGAAA p.Glu55Argfs*20 5 1 (F) Yes No
No functional protein c.175C > T p.Arg59* 5 5 (4 and 1 M) Yes Yes [4,18,19]
No functional protein c.183delT p.Met63Cysfs*13 5 2 (F, twins) Yes Yes [4]
No functional protein c.220G > T p.Glu74* 5 1 (F) No No
No functional protein c.282 + 3_282 + 6delAAGT p.(Asn50Tyrfs*15) 5 2 (F) Yes Yes [4]
No functional protein c.283-3_290del p.(Asn95Ilefs*2) 5 2 (F, sisters) Yes Yes [2,4]
No functional protein c.339ins1 p.? 6 1 (F) No No
No functional protein c.351 T > A p.Tyr117* 6 1 (M) No No
No functional protein c.400C > T p.Arg134* 6 2 (F and M) Yes Yes [4,20]
No functional protein c.456_457delTG p.Cys152* 7 1 (F) No No
No functional protein c.464-2A > G p.Gly155Alafs*43 7 1 (M) Yes No
No functional protein c.506_507delAC p.Thr168Argfs*36 8 1 (F) No No
Missense/in-frame mutation
within catalytic domain
c.38 T > C p.Phe13Ser 2 1 (F) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain





p.(Lys33dup) 4 1 (F) No No
Missense/in-frame mutation
within catalytic domain
c.119C > T p.Ala40Val 4 1 (F) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain
c.191 T > C p.Leu64Pro 5 1 (M) Yes Yes [4,21]
Missense/in-frame mutation
within catalytic domain
c.214_216del p. Ile72del 5 1 (F) No No
Missense/in-frame mutation
within catalytic domain
c.215 T > C p.Ile72Thr 5 1 (F) Yes No
Missense/in-frame mutation
within catalytic domain
c.364G > A p.Ala122Thr 6 1 (F) Yes Yes [4]
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Table 1 Distribution of CDKL5 mutations within our study group (Continued)
Missense/in-frame mutation
within catalytic domain
c.377G > A p.Cys126Tyr 6 1 (F) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain
c.395 T > G p.Val132Gly 6 1 (F) No No
Missense/in-frame mutation
within catalytic domain
c.404A > G p.(Asp135_Phe154del) 7 1 (M) No No
Missense/in-frame mutation
within catalytic domain
c.404-3C > A p.(Asp135_Phe154del) 7 1 (F) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain
c.428 T > A p. Ile143Asn 7 1 (F) No No
Missense/in-frame mutation
within catalytic domain
c.458A > T p. Asp153Val 7 1 (F) No No
Missense/in-frame mutation
within catalytic domain
c.463 + 1G > A p.Asp135_Phe154del 7 1 (F) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain
c.473G > C p.Arg158Pro 8 1 (M) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain
c.514G > A p.Val172Ile 8 1 (M) No No
Missense/in-frame mutation
within catalytic domain
c.526 T > C p.Trp176Arg 8 1 (F) No No
Missense/in-frame mutation
within catalytic domain
c.532C > T p.Arg178Trp 8 2 (F) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain
c.536C > T p. Ser179Phe 8 1 (F) No No
Missense/in-frame mutation
within catalytic domain
c.577G > C p.Asp193His 9 1 (F) No No
Missense/in-frame mutation
within catalytic domain
c.587C > T p.Ser196Leu 9 5 (F) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain
c.595 T > C p.Cys199Arg 9 1 (F) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain
c.620G > A p.Gly207Glu 9 1 (F) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain
c.656A > C p.Gln219Pro 9 1 (F) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain
c.680 T > C p.Leu227Pro 9 1 (F) Yes Yes [4]
Missense/in-frame mutation
within catalytic domain
c.872G > A p.Cys291Tyr 11 1 (F) Yes No
Truncation occurring between
aa 172 and 781
c.670C > T p.Gln224* 9 1 (M) No No
Truncation occurring between
aa 172 and 781
c.556_557delGC p.Ala186Serfs*19 9 1 (M) No No
Truncation occurring between
aa 172 and 781
c.745-?_977 + ?del p.(Phe249Lysfs*16) 10–11 1 (F) No No
Truncation occurring between
aa 172 and 781
c.801_802delAT p.Asn267Lysfs*5 11 1 (F) No No
Truncation occurring between
aa 172 and 781
c.857dupA p.Tyr286* 11 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.859_868del10 p.Leu287Serfs*3 11 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.978-?_2980 + ?del p.? 12+ 1 (F) No No
Truncation occurring between
aa 172 and 781
c.1039C > T p.Gln347* 12 1 (F) Yes No
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Truncation occurring between
aa 172 and 781
c.1371dupA p.Leu458Thrfs*5 12 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.1375C > T p.Gln459* 12 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.1446delC p.Tyr482* 12 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.1470_1471delGG p.Ala491Thrfs*3 12 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.1499ins4 p.? 12 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.1547_1554del8 p.Tyr516Phefs*2 12 1 (F) No No
Truncation occurring between
aa 172 and 781
c.1581del p.Pro527fs 12 1 (F) No No
Truncation occurring between
aa 172 and 781
c.1648C > T p.Arg550* 12 4 (F) Yes Yes (1 child [4])
Truncation occurring between
aa 172 and 781
c.1671dupA p.Arg558Thrfs*9 12 1 (F) Yes No
Truncation occurring between
aa 172 and 781
c.1675C > T p.Arg559* 12 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.1782 T > G p.Tyr594* 12 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.1791delC p.Tyr598Thrfs*18 12 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.2038A > T p.Lys680* 13 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.2047-1G > A p.Gly683Valfs*101 13 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.2047-2A > G p.Gly683Cysfs*66 13 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.2072_2073delCT p.Ser691* 14 1 (F) Yes Yes [4]
Truncation occurring between
aa 172 and 781
c.2258_2259delAA p.Gln753Profs*10 15 1 (F) No No
Truncation occurring between
aa 172 and 781
c.2376 + 5G > A p.(Lys760Tyrfs*10) 16 1 (F) Yes Yes [4]
Late truncation after aa 781 c.2374dupA p.Thr792Asnfs*9 16 1 (F) Yes Yes [4]
Late truncation after aa 781 c.2377-8 T > A p.(Val793Leufs*2) 16 1 (F) No No
Late truncation after aa 781 c.2413C > T p.Gln805* 17 1 (M) No No
Late truncation after aa 781 c.2420_2430del p.Ser807Cysfs*2 17 1 (M) No No
Late truncation after aa 781 c.2504delC p.Pro835Hisfs*2 17 1 (F) Yes Yes [4]
Late truncation after aa 781 c.2477-?_2713 + ?del p.(Ser833Thrfs*22) 17 2 (F) No No
Late truncation after aa 781 c.2564C > G p.Ser855* 18 2 (F) Yes Yes [4]
Late truncation after aa 781 c.2572delC p.Arg858Alafs*5 18 1 (F) Yes Yes [4]
Late truncation after aa 781 c.2635_2636delCT p.Leu879Glufs*30 18 2 (F) Yes Yes [4]
Late truncation after aa 781 c.2711delC p.Pro904Glnfs*23 18 1 (F) Yes Yes [4]
Mutations not grouped
c.1612A > G p.Thr538Ala 1 1 (M) No No
c.2684C > T p.Pro895Leu 18 1 (F) No No
c.65-?_1944 + ?dup p.(?) 3–12 1 (M) No No
c.146-?_463 + ?dup p.(?) 5–7 1 (F) No No
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Table 1 Distribution of CDKL5 mutations within our study group (Continued)
(Position uncertain) p.(?) 1–3 1 (M) Yes Yes [4]
c.745-2A > G p.(Phe249_Lys275del) 10 1 (F) Yes Yes [4]
c.825 + 1G > A p.(Phe249_Lys275del) 10 1 (F) Yes Yes [4]
c.825 + 1G > T p.(Phe249_Lys275del) 10 1 (F) Yes No
c.1030_1031insGAC p.Lys344delinsArgGln 12 1 (F) Yes Yes [4]
c.2276 + 1G > A p.(Val718_Trp759delinsGly) 15 1 (F) Yes Yes [4]
CDKL5 numbering based on GenBank reference sequences NG_008475.1 and NM_003159.2, with the first A in the start codon numbered +1. Protein names in
brackets indicate inferred changes based on in silico analyses, including splicing predictions by SpliceSiteFinder-like (accessed through Alamut Visual v2.3.4), MaxEntScan
[22], NNSPLICE by the Berkeley Drosophila Genome Project [23], GeneSplicer [24] and Human Splicing Finder [25].
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1/20 females was able to walk independently, a quarter
had reported functional hand use and a quarter could use
babble or single words [3]. The increased number of par-
ticipants in our study compared to the French study isTable 2 Pathogenicity of missense mutations within our curre
Nucleotide
change (cDNA)
Protein change SIFT (score 1–0) MutationTaster (p
c.38 T > C p.Phe13Ser Deleterious (0) Disease-causing (0.
c.58G > C p.Gly20Arg Deleterious (0) Disease-causing (1)
c.119C > T p.Ala40Val Tolerated (0.12) Disease-causing (0.
c.191 T > C p.Leu64Pro Deleterious (0) Disease-causing (1)
c.364G > A p.Ala122Thr Deleterious (0) Disease-causing (1)
c.377G > A p.Cys126Tyr Deleterious (0) Disease-causing (1)
c.395 T > G p.Val132Gly Deleterious (0) Disease-causing (1)
c.428 T > A p. Ile143Asn Deleterious (0) Disease-causing (1)
c.458A > T p. Asp153Val Deleterious (0) Disease-causing (1)
c.473G > C p.Arg158Pro Deleterious (0) Disease-causing (1)
c.514G > A p.Val172le Deleterious (0) Disease-causing (1)
c.526 T > C p. Trp176Arg Deleterious (0) Disease-causing (1)
c.532C > T p.Arg178Trp Deleterious (0) Disease-causing (1)
c.536C > T p. Ser179Phe Deleterious (0) Disease-causing (1)
c.577G > C p.Asp193His Deleterious (0) Disease-causing (1)
c.587C > T p.Ser196Leu Deleterious (0) Disease-causing (1)
c.595 T > C p.Cys199Arg Deleterious (0) Disease-causing (1)
c.620G > A p.Gly207Glu Deleterious (0) Disease-causing (1)
c.656A > C p.Gln219Pro Deleterious (0) Disease-causing (1)
c.680 T > C p.Leu227Pro Deleterious (0) Disease-causing (1)
c.2684C > T p.Pro895Leu Deleterious (0.03) Disease causing (1)
c.872G > A p.Cys291Tyr Deleterious (0.01) Disease causing (1)
c.215 T > C p.Ile72Thr Deleterious (0) Disease-causing (1)
c.1612A > G p.Thr538Ala Deleterious (0.04) Polymorphism (1)
c.526 T > C p.Trp167Arg Deleterious (0) Disease causing (1)
CDKL5 numbering based on GenBank reference sequences NG_008475.1 and NM_003
carried out through Alamut Visual (v2.4) using SIFT (scale: 1 = tolerated, 0 = deleterious
0 = low confidence, 1 = high confidence) [27], PolyPhen2 (HumVar module, scale: 0 = b
C65 = pathogenic) [29].one likely explanation for the differing results. However,
age may also be a factor as the median age of the females
in the French study (4.5 years) was 2 years less than in
ours. We have shown that there is a delay in the age of ac-
quiring these developmental milestones and thereforent sample of individuals with the CDKL5 disorder
value 0–1) PolyPhen2 (score 0–1) Align GVGD (Class C0–C65)
999) Probably damaging (0.999) Benign (C0)
Probably damaging (0.985) Benign (C0)
999) Probably damaging (0.999) Benign (C0)
Probably damaging (1) Benign (C0)
Probably damaging (0.999) Likely pathogenic (C55)
Probably damaging (1) Pathogenic (C65)
Probably damaging (1) Pathogenic (C65)
Possibly damaging (0.9) Benign (C0)
Benign (0.07) Benign (C0)
Probably damaging (0.999) Benign (C0)
Probably damaging (0.995) Benign (C0)
Probably damaging (0.999) Benign (C0)
Probably damaging (1) Benign (C0)
Probably damaging (0.999) Likely benign (C15)
Probably damaging (1) Pathogenic (C65)
Probably damaging (0.976) Pathogenic (C65)
Probably damaging (0.999) Pathogenic (C65)
Probably damaging (1) Pathogenic (C65)
Probably damaging (0.996) Pathogenic (C65)
Probably damaging (0.996) Pathogenic (C65)
Possibly damaging (0.578) Benign (C0)
Probably damaging (0.930) Benign (C0)
Possibly damaging (0.578) Benign (C0)
Benign (0.009) Benign (C0)
Probably damaging (0.999) Benign (C0)
159.2, with the first A in the start codon numbered +1. In silico predictions are
) [26], MutationTaster (p value for prediction confidence (not pathogenicity):
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Figure 2 The proportion of females and males with the CDKL5 disorder who attained developmental milestones by various ages.
Legend: A: independent sitting, B: independent standing, C: independent walking, D: raking grasp, E: pincer grip, F: babble, G: single words.
Fehr et al. Journal of Neurodevelopmental Disorders 2015, 7:2 Page 8 of 13
http://www.jneurodevdisorders.com/content/7/1/2some of the girls in the French study may be yet to acquire
these abilities. There also appears to be a ‘cohort’ effect in
our data, with some of our older females (13 years and
older) appearing to have attained less developmental mile-
stones than those in the younger age group (7 to 13 years).
In the past, children and adults with severe undiagnosed
epilepsy disorders were targeted for screening for muta-
tions in the CDKL5 gene. With advances in genetic tech-
nologies, less severely affected children are being tested
and identified, thus increasing the variability seen initially
in children with the CDKL5 disorder. Regardless, it is im-
portant that this variability in functional ability be recog-
nised both by clinicians and researchers.
In our study, the males with the CDKL5 disorder had
more impaired development than the females. Again,
there was variability, with some of the males having less
impaired development. Half of the boys in our study had
attained rolling, a quarter learned to sit independently by
1 year 3 months and a quarter used babble by 7 months
(earlier than the females in our group). There were four
boys in our study who had attained more developmentalmilestones. The first was a 10-month old who could sit in-
dependently, babble and transfer objects from hand to
hand (c.400C > T, p.Arg134*). The second was a 2 and a
half year old who could stand independently, transfer
objects from hand to hand and babbled (c.351 T > A,
p.Tyr117*). The third was a 3 and a half year old who
could sit independently, had limited hand use and could
use single words (c.1612A >G, p.Thr538Ala). The fourth
was a 4 and a half year old who had never had epilepsy,
could walk independently (even run) and had a pincer grip
but had language impairment (babble only) (c.514G >A,
p.Val172Ile). There have been few boys with the CDKL5
disorder described in the literature [7,9,12,18,32-38].
A recent study by Mirzaa and colleagues reported eight
males with the CDKL5 disorder whose ages ranged from
2 months to 14 years (median age 5 years) [36]. These
boys were described as having profound developmental
delay, with impaired or absent language and motor abil-
ities. The authors concluded that boys with the CDKL5
disorder are severely affected and have minimal acquisi-
tion of developmental skills. In our study, around half of
Table 3 The proportion of individuals with the CDKL5 disorder of a particular current age who had attained various
gross motor, communication and hand milestones
Age at completion of questionnaire


















Roll front to back 4 (36.4) 1 (100) 46 (92) 5 (50) 27 (84) 2 (40) 14 (88) 1 (50)
Roll back to front 5 (45) 1 (100) 47 (94) 5 (50) 26 (81) 2 (40) 14 (88) 1 (50)
Transition from sitting to crawling position 1 (9) 1 (100) 23 (46) 3 (30) 16 (50) 0 (0) 5 (31) 1 (50)
Crawl 1 (9) 0 (0) 12 (24) 2 (20) 10 (31) 0 (0) 4 (25) 1 (50)
Stand with support 2 (18) 1 (100) 37 (74) 3 (30) 22 (69) 1 (20) 10 (63) 1 (50)
Pull to stand 1 (9) 0 (0) 13 (26) 2 (20) 14 (44) 1 (20) 6 (38) 1 (50)
Walk with support 1 (9) 0 (0) 24 (48) 1 (10) 16 (50) 1 (20) 8 (50) 1 (50)
Fine motor
Transfer from hand to hand 3 (27) 1 (100) 25 (50) 2 (20) 18 (56) 0 (0) 8 (50) 0 (0)
Play with blocks 0 (0) 0 (0) 8 (16) 1 (10) 8 (25) 0 (0) 2 (13) 0 (0)
Social and communication
Social smile 8 (73) 1 (100) 38 (76) 7 (70) 18 (56) 1 (20) 9 (56) 0 (0)a
Fix and follow 3 (30.0)a 1 (100) 39 (78) 4 (40) 23 (72) 1 (20) 10 (67)a 1 (100)a
Wave goodbye 0 (0.0) 0 (0) 11 (22) 1 (10) 4 (13) 0 (0) 1 (6) 0 (0)
Respond to own name 4 (36) 1 (100) 33 (66) 3 (33.3)a 20 (63) 2 (40) 9 (56) 0 (0)
Point to things that he/she wants 0 (0.0) 0 (0) 6 (12) 1 (10) 8 (26)a 0 (0) 2 (13) 0 (0)
Respond to others emotions 4 (36) 1 (100) 23 (47)a 4 (40) 11 (34) 1 (20) 4 (25) 1 (50)
Respond to ‘no’ 2 (18) 0 (0) 16 (32) 2 (25)a 13 (41) 0 (0) 4 (25) 0 (0)
Phrases 0 (0.0) 0 (0) 3 (6) 0 (0) 3 (9) 0 (0) 1 (6) 0 (0)
aThe denominator in this group varies.
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http://www.jneurodevdisorders.com/content/7/1/2the males also had minimal acquisitions of developmental
skills; however, the other half did attain some milestones.
These findings show the variability in the acquisition of
developmental milestones in males with the CDKL5 dis-
order. Although the males are generally more severe than
females, more males achieved developmental milestonesTable 4 The relationship between genotype and developmen
Milestone No functional protein Missense/in-frame mutati
within catalytic domain
Number (%) Median age skill
attained (years)
Number (%) Median age
attained (ye
Sitting 17/33 (52) 2 18/27 (67) 3
Standing 6/32 (19) - 5/28 (18) -
Walking 6/34 (18) - 4/28 (14) -
Babble 13/29 (45) - 13/27 (48) 6
Single words 4/32 (13) - 3/28 (11) -
Raking grasp 12/29 (44) 7 16/25 (64) 4
Pincer grasp 3/32 (9) - 2/28 (7) -
(-) Values blank as less than 50% attained the particular skill.in our present study than previously reported. Our sample
of boys was double that of the previously reported study,
and so again increased sample size may be a key factor in
being able to demonstrate this variability. Age could also
be a factor, however the median ages of the boys in our
and the US study [36] were similar (4.3 years and 5 years).tal milestone acquisition in females
on Truncation between aa 172
and aa 781 inclusive
Truncation after aa 781
skill
ars)
Number (%) Median age skill
attained (years)
Number (%) Median age skill
attained (years)
10/26 (38) - 10/12 (83) 1.2
8/28 (29) - 5/10 (50) 5
6/28 (21) - 5/12 (42)
12/25 (44) - 4/8 (50) 1
6/28 (21) - 3/10 (30)
8/22 (36) 12 7/9 (78) 2
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Figure 3 The influence of mutation type of the proportion of females with the CDKL5 disorder who attained developmental milestones by
various ages. Legend: A: independent sitting, B: independent standing, C: independent walking, D: raking grasp, E: pincer grip, F: babble, G: single words.
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http://www.jneurodevdisorders.com/content/7/1/2It is likely that the previously described ‘cohort effect’ may
also be impacting on the variability seen in our male sam-
ple. The majority of males in the literature were identified
through screening groups of severely affected individuals
for CDKL5 mutations. Advances in genetic technology for
diagnostic purposes mean those children who would pre-
viously never have been identified, such as our young boy
who could run and who had never been diagnosed with
epilepsy, are being diagnosed. These findings suggest that
a different spectrum of boys with the CDKL5 disorder,
who until now have not been diagnosed, may exist.
Our understanding of the functional role of CDKL5 is
still limited, but CDKL5 has been shown to be involved in
neuronal cell differentiation and proliferation, dendritic
arborisation and dendritic spine morphology [39-41]. It is
likely that mutations affecting the function of CDKL5 are
likely to impair neuronal development and subsequent at-
tainment of developmental milestones. The occurrence of
early refractory epilepsy in the CDKL5 disorder may also
contribute to the altered neuronal function, with seizures
shown to impact developmental programming [42]. Whetherthe impairment seen in the CDKL5 disorder is a direct re-
sult of the occurrence of infantile seizures, resulting in an
epileptic encephalopathy, or whether it is a consequence
of the underlying gene mutation, is yet to be determined
and further research in this area is needed.
The relationship between genotype and phenotype in
the CDKL5 disorder has only been specifically investi-
gated in one other study [43]. This study identified 12 pa-
tients (from a total of 26 with a mutation) who had one of
eight recurrent mutations previously described in the lit-
erature. These 12 patients were pooled with an additional
14 individuals previously described in the literature. The
authors found that those with the p.Ala40Val, which is a
missense mutation within the ATP binding site of the kin-
ase domain, had a milder phenotype (phenotype severity
based on factors such as gross motor ability, hand func-
tion, stereotypies and seizure severity) than those with a
missense mutation elsewhere in the kinase domain or a
frameshift within the C-terminal region. Due to the het-
erogeneity of mutations within the CDKL5 disorder, we
chose not to investigate specific mutations, rather, we
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http://www.jneurodevdisorders.com/content/7/1/2pooled together different types that were predicted to have
similar functional/structural consequences. This hetero-
geneity means that genotype/phenotype studies will be
more difficult to conduct unless larger numbers of indi-
viduals are ascertained. We found no clear relationship
between genotype and phenotype in our study, but there
were a few differences between the groups. Females with a
truncation between aa 172 and aa 781 attained fewer de-
velopmental milestones, similar to that of those who
lacked the entire CDKL5 gene. Earlier research suggested
that loss of the C-terminal region can in fact act as a loss
of function mutation due to loss of localisation ability
and increased self-phosphorylation (increased capacity to
phosphorylate the kinase itself ) [16,44]. One difference we
found was that individuals with a truncating mutation
after aa 781, such as the mutation c.2635_2636delCT, ap-
peared to attain more milestones overall. This differs
from the previous study, which found that girls with this
mutation were more severely affected and unable to walk
[43]. No clear conclusion can be drawn on the role of geno-
type until even larger studies are undertaken and other
previously identified factors (such as epilepsy) are consid-
ered, although it does appear as though genotype may
have a part to play in the clinical variability in the CDKL5
disorder.
Our study is the first major international data collec-
tion of individuals with the CDKL5 disorder. This gives
us the advantage of having the largest data collection on
individuals with the CDKL5 disorder. Our data collec-
tion tools were also designed to capture clinical informa-
tion specific to the CDKL5 disorder, not other disorders
such as RTT. It is apparent that there is much variability
within this disorder, and therefore larger numbers are
still needed to provide a more comprehensive represen-
tation of the clinical presentation. Recall error, especially
for caregivers with older children, is likely. We have limited
this by asking caregivers to refer to their child’s medical re-
cords and diaries before completing the questionnaire. Be-
cause these children exhibit symptoms from an early age,
developmental gains are most likely to be well recorded, as
caregivers are paying special attention to their child’s de-
velopment. We found that many parents knew whether
their child attained a particular milestone, but the age that
these skills were attained was not always known, which is
demonstrated by the missing data in our study. Changes in
diagnostic technology and increased awareness of the
CDKL5 disorder mean that children are being diagnosed
younger, and a more variable spectrum is being identified.
This results in the ‘cohort effect’ to which we have alluded,
where the younger are less severe than previously diag-
nosed children. The identification of younger children
means that this data collection will have the capacity to
collect prospective data on developmental milestones. Fi-
nally, our study will only reach caregivers of individualswho have access to the internet and therefore selection
bias exists in that regard.
Conclusion
Understanding the acquisition of gross motor milestones
in the CDKL5 disorder is valuable information for care-
givers, their therapists and clinicians and shows that for
most, skills are attained at a much later age. It would be
of interest to further investigate the events surrounding
the acquisition of these milestones, especially with regard
to seizure control. For caregivers, our data provide hope
that their young child may still attain milestones at a later
age than is usual for the general population. As the data-
base grows, it will be important, to further examine the re-
lationship between genotype and functional abilities.
Individuals with the CDKL5 disorder have previously been
described as having severely impaired development. Our
findings show the variability within this disorder and sug-
gest that there may be children with the CDKL5 disorder
who present differently to the clinical picture originally
described. Although we found no clear relationship be-
tween genotype and phenotype, the differences between
individuals suggest that with greater numbers such a rela-
tionship may be identified. Continued research into the
natural history of the CDKL5 disorder is needed to
further our understanding of the variability seen within
this condition.
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